title: Familial xanthomatous hypercholesterolemia: abnormal exogenous lipid metabolism evidenced by the vitamin A test.
abstract: Familial xanthomatous hypercholesterolemia is a metabolic disorder associated with high LDL levels attributed to a familial defect in LDL receptor activity. We have previously shown that hyperlipoproteinemia of WHHL rabbits, considered to be a model for heritable hypercholesterolemia, was at least partly of exogenous origin. We have though studied retinyl palmitate (RP) levels 12 h after a standardized mixed meal as a simple test to detect abnormalities of intestinal-derived lipoprotein clearance in 22 familial hypercholesterolemic patients with xanthomatosis (13 of them treated by simvastatin, an HMGCoA reductase inhibitor, and 9 not treated), as compared to a control group (n = 12). Total and LDL cholesterol, plasma triglyceride and apo B levels were significantly higher in patients when compared to controls. Mean RP levels appeared higher in familial hypercholesterolemic patients, when compared to controls, with 6 among 22 patients showing clearly high vitamin A levels and 4 borderline values, whereas high triglyceride levels (> 2 g/l) were detected in only 1 patient. No patients within the group with high vitamin A levels showed an apo E2/E2 phenotype. Vitamin A levels correlated with plasma triglycerides in the whole group of subjects (r = 0.50, p < 0.05). No difference was observed in vitamin A distribution between treated and untreated hypercholesterolemic patients. Our results indicate that the clearance of RP-labeled intestinal lipoproteins is delayed in some xanthomatous familial hypercholesterolemic patients as compared with that of controls. These findings suggest that familial xanthomatous hypercholesterolemia may be heterogenous concerning physiopathological mechanisms inducing hyperlipidemia.
authors.affiliation: Unité de Recherches sur les Dyslipidémies et l'Athérosclérose (INSERM U 32, Créteil, France.
authors.forename: F
authors.initials: F
authors.lastname: Assadollahi
authors.forename: E
authors.initials: E
authors.lastname: Cavallero
authors.forename: J C
authors.initials: JC
authors.lastname: Buxtorf
authors.forename: B
authors.initials: B
authors.lastname: Jacotot
authors.forename: J L
authors.initials: JL
authors.lastname: Beaumont
mesh_terms: D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D004435:Eating; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000150:complications / Q000235:genetics / Q000378:metabolism*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D050356:Lipid Metabolism; D008055:Lipids / Q000494:pharmacology; D008148:Lovastatin / Q000031:analogs & derivatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D019821:Simvastatin; D014280:Triglycerides / Q000097:blood; D014801:Vitamin A / Q000097:blood* / Q000494:pharmacology; D015223:Wolman Disease / Q000150:complications / Q000235:genetics / Q000378:metabolism*
chemical_list: D001055:Apolipoproteins B; D000960:Hypolipidemic Agents; D008055:Lipids; D014280:Triglycerides; D014801:Vitamin A; D008148:Lovastatin; D019821:Simvastatin